Alethea Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Alethea Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,517	Closed	-$337K	–	92
2018 Q3	$337K	Hold	3,517	–	–	0.51%	62
2018 Q2	$335K	Sell	3,517 -10,344	-75%	-$951K	0.57%	53
2018 Q1	$1.22M	Hold	13,861	–	–	1.65%	14
2017 Q4	$1.18M	Buy	+13,861	New	+$1.16M	1.87%	9

Other funds holding XBI

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Alethea Capital Management's XBI Position: Q4 2018 in Review

Alethea Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 3,517 shares — an estimated $337K sold.

Alethea Capital Management first reported a position in XBI in Q4 2017 and held it in 4 quarters. The position peaked at $1.22M in Q1 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

Alethea Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
Alethea Capital Management sold 3,517 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $337K.
Alethea Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 4 quarters.
Alethea Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.22M in Q1 2018.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on Alethea Capital Management's 13F filing for Q4 2018, filed 23 Jan 2019.